Inhibrx Biosciences, Inc. INBX 深 滬
等待開盤 05-21 09:30:00 美东时间
107.27
-2.240
-2.05%
華盛通- 最 高113.95
- 今 開110.98
- 成交量 27.29万股
- 最 低 104.42
- 昨 收 109.51
- 總市值 15.74亿
- 52周最高 155.29
- 市盈率 靜 --
- 換手率 1.86%
- 52周最低 12.72
- 委 比 97.07%
- 總股本 1467.12万
- 歷史最高 155.29
- 量 比 0.81
- 振 幅 8.70%
- 歷史最低 7.67
- 每 手 1
- 風險率 32.86%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多OX40激动剂联合K药头颈癌疗效翻倍，沉寂15年的OX40靶点终迎破局！
（来源：ACROBiosystems官方） 2026年5月，Inhibrx Biosciences（纳斯达克代码：INBX）公布了备受瞩目的HexAgon研究...
05-20 18:10
Inhibrx Biosciences GAAP EPS of -$2.15
Inhibrx Biosciences press release (INBX): Q1 GAAP EPS of -$2.15. Cash and Cash Equivalents. As of March 31, 2026, the Company had cash and cash equivalents of $161.7 million, as compared to $124.2 mil...
05-15 04:46
Inhibrx Biosciences Q1 EPS $(2.15) Misses $(1.79) Estimate
Inhibrx Biosciences (NASDAQ:INBX) reported quarterly losses of $(2.15) per share which missed the analyst consensus estimate of $(1.79) by 20.11 percent. This is a 23.21 percent increase over losses of $(2.80) per share
05-15 04:38
美股夜盘 | Fundrise Innovation Fund, LLC涨16.13%，奇景光电涨11.30%
Fundrise Innovation Fund, LLC涨16.13%；奇景光电涨11.30%；Inhibrx Biosciences, Inc.涨11.28%
05-11 13:01
美股夜盘 | Inhibrx Biosciences, Inc.涨10.90%，最新股价149.0美元
Inhibrx Biosciences, Inc.涨10.90%，报149.0美元
05-11 11:02
美股夜盘 | Rackspace Technology, Inc.涨16.39%，Fundrise Innovation Fund, LLC涨15.71%
Rackspace Technology, Inc.涨16.39%；Fundrise Innovation Fund, LLC涨15.71%；奇景光电涨14.45%
05-11 10:01
美股夜盘 | Fundrise Innovation Fund, LLC涨15.19%，Rackspace Technology, Inc.涨13.84%
Fundrise Innovation Fund, LLC涨15.19%；Rackspace Technology, Inc.涨13.84%；Penguin Solutions Incorporation涨13.36%
05-11 09:01
Inhibrx Biosciences To Present Interim Phase 2 HexAgon Study Results For INBRX-106 Plus Keytruda In Head And Neck Cancer On May 11, 2026 Webcast
– Event to be webcast live on Monday, May 11, 2026, at 5:30 a.m. PT –SAN DIEGO, May 8, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company
05-09 04:01
Pfizer Says Cancer Therapy Beats Standard Therapy In Late-Stage Blood Cancer Study
Pfizer reports Phase 3 data showing ELREXFIO improved progression-free survival versus standard therapy in multiple myeloma study.
04-30 02:41
Adagio Medical Heart Ablation System Shows 84% Freedom From Shock
Adagio Medical shares rise after vCLAS trial shows strong VT outcomes, reduced drug use, and lower readmissions ahead of FDA review.
04-27 19:55
